Published in Health and Medicine Week, July 28th, 2003
"Current guidelines for the treatment of moderate persistent asthma list the combination of long-acting beta-agonists and inhaled corticosteroids (ICSs) as the treatment of choice.
"This decision is based on their efficacy, compared with other dual controller combinations such as increased doses of ICSs or adding leukotriene modifiers, especially when the forced expiratory volume in 1 second value is used as the primary comparator. The main purpose of this study is to examine this form of dual controller therapy in terms of anti-inflammatory effects,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.